GPP
SRPT icon

Great Point Partners’s Sarepta Therapeutics SRPT Stock Holding History

Great Point Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-238,900
Closed -$4.56M – 45
2016
Q2 		$4.56M Buy
238,900
+88,900
+59% +$1.65M 1.3% 19
2016
Q1 		$2.93M Buy
+150,000
New +$2.62M 1.05% 24

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Great Point Partners's SRPT Position: Q1 2024 in Review

Great Point Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 80,000 shares — an estimated $7.71M sold.

Great Point Partners first reported a position in SRPT in Q3 2017 and held it in 7 quarters. The position peaked at $20M in Q3 2023. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Great Point Partners reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Great Point Partners sold 80,000 Sarepta Therapeutics shares in Q1 2024, an estimated $7.71M.
  • Great Point Partners first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 7 quarters.
  • Great Point Partners's Sarepta Therapeutics position peaked at $20M in Q3 2023.
  • 415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.